Increased synthesis of Mcl-1 protein underlies initial survival of EGFR-mutant lung cancer to EGFR inhibitors and provides a novel drug target

Kyung A. Song, Yasuyuki Hosono, Crystal Turner, Sheeba Jacob, Timothy L. Lochmann, Yoshiko Murakami, Neha U. Patel, Jungoh Ham, Bin Hu, Krista M. Powell, Colin M. Coon, Brad E. Windle, Yuko Oya, Jennifer E. Koblinski, Hisashi Harada, Joel D. Leverson, Andrew J. Souers, Aaron N. Hata, Sosipatros Boikos, Yasushi YatabeHiromichi Ebi, Anthony C. Faber

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Abstract

Purpose: EGFR inhibitors (EGFRi) are effective agains EGFR-mutant lung cancers. The efficacy of these drugs, how ever, is mitigated by the outgrowth of resistant cells, most often driven by a secondary acquired mutation in EGFR, T790M. We recently demonstrated that T790M can arise de novo during treatment; it follows that one potential therapeutic strategy to thwart resistance would be identifying and eliminating these cells [referred to as drug-tolerant cells (DTC)] prior to acquir ing secondary mutations like T790M. Experimental Design: We have developed DTCs to EGFR in EGFR-mutant lung cancer cell lines. Subsequent analyses o DTCs included RNA-seq, high-content microscopy, and pro tein translational assays. Based on these results, we tested the ability of MCL-1 BH3 mimetics to combine with EGFR inhi bitors to eliminate DTCs and shrink EGFR-mutant lung cance tumors in vivo. Results: We demonstrate surviving EGFR-mutant lung cancer cells upregulate the antiapoptotic protein MCL-1 in response to short-term EGFRi treatment. Mechanistically, DTCs undergo a protein biosynthesis enrichment resulting in increased mTORC1-mediated mRNA translation of MCL-1, revealing a novel mechanism in which lung cancer cells adapt to short-term pressures of apoptosis-inducing kinase inhibitors. Moreover, MCL-1 is a key molecule governing the emergence of early EGFR-mutant DTCs to EGFRi, and we demonstrate it can be effectively cotargeted with clinically emerging MCL-1 inhibitors both in vitro and in vivo. Conclusions: Altogether, these data reveal that this novel therapeutic combination may delay the acquisition of secondary mutations, therefore prolonging therapy efficacy.

Original languageEnglish
Pages (from-to)5658-5672
Number of pages15
JournalClinical Cancer Research
Volume24
Issue number22
DOIs
Publication statusPublished - Nov 15 2018
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Increased synthesis of Mcl-1 protein underlies initial survival of EGFR-mutant lung cancer to EGFR inhibitors and provides a novel drug target'. Together they form a unique fingerprint.

Cite this